Phase I/II Clinical Trial of Daratumumab and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia Post-Allogeneic Hematopoietic Stem Cell Transplant
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 06 Feb 2019
At a glance
- Drugs Daratumumab (Primary) ; T cell replacement therapy (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 29 Jan 2019 Planned initiation date changed from 31 Dec 2018 to 28 Feb 2019.
- 19 Nov 2018 Planned initiation date changed from 1 Sep 2018 to 31 Dec 2018.
- 13 Aug 2018 Planned initiation date changed from 1 Jun 2018 to 1 Sep 2018.